Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · Real-Time Price · USD
101.94
-2.10 (-2.02%)
At close: Apr 28, 2026, 4:00 PM EDT
101.94
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:47 PM EDT
Nuvalent Employees
Nuvalent had 228 employees as of December 31, 2025. The number of employees increased by 86 or 60.56% compared to the previous year.
Employees
228
Change (1Y)
86
Growth (1Y)
60.56%
Revenue / Employee
n/a
Profits / Employee
-$1,865,689
Market Cap
8.01B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 228 | 86 | 60.56% |
| Dec 31, 2024 | 142 | 50 | 54.35% |
| Dec 31, 2023 | 92 | 30 | 48.39% |
| Dec 31, 2022 | 62 | 22 | 55.00% |
| Dec 31, 2021 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 925 |
| ImmunityBio | 691 |
| Cytokinetics | 673 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
| Kymera Therapeutics | 238 |
NUVL News
- 7 days ago - Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting - PRNewsWire
- 11 days ago - New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 - PRNewsWire
- 21 days ago - Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC - PRNewsWire
- 6 weeks ago - Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 - PRNewsWire
- 7 weeks ago - Nuvalent Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Nuvalent Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 2 months ago - Nuvalent Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026 - Transcripts